Tassos Gianakakos
Chief Executive Officer bei MYOKARDIA, INC.
Vermögen: 117 331 $ am 31.03.2024
Profil
Derzeit hat Anastasios E. Gianakakos die Position des Chief Executive Officer bei MyoKardia, Inc. inne. Er ist auch im Vorstand von LianBio. In der Vergangenheit war Anastasios E. Gianakakos President & Senior VP-Business Development bei Codexis, Inc. und Prozessingenieur bei Merck & Co, Inc. sowie Director -Business Development bei Maxygen, Inc. und Chief Business Officer & Senior Vice President bei MAP Pharmaceuticals LLC. Er erhielt einen Undergraduate-Abschluss vom Massachusetts Institute of Technology, einen Graduate-Abschluss von der Northwestern University und einen MBA von der Harvard Business School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LIANBIO
0,35% | 15.02.2024 | 363 253 ( 0,35% ) | 117 331 $ | 31.03.2024 |
Aktive Positionen von Tassos Gianakakos
| Unternehmen | Position | Beginn |
|---|---|---|
| MYOKARDIA, INC. | Chief Executive Officer | 01.10.2013 |
| LIANBIO | Director/Board Member | 01.08.2020 |
Prolaio, Inc.
 Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | President | - |
Ehemalige bekannte Positionen von Tassos Gianakakos
| Unternehmen | Position | Ende |
|---|---|---|
MAP Pharmaceuticals LLC
 MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Corporate Officer/Principal | 01.03.2013 |
| MERCK & CO., INC. | Chief Tech/Sci/R&D Officer | 01.01.1997 |
| CODEXIS, INC. | President | - |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - |
Ausbildung von Tassos Gianakakos
| Massachusetts Institute of Technology | Undergraduate Degree |
| Northwestern University | Graduate Degree |
| Harvard Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| CODEXIS, INC. | Process Industries |
| Private Unternehmen | 5 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
| LianBio | |
Prolaio, Inc.
Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | Health Technology |
